Description: Listen to an expert clinician discussion an add-on maintenance treatment for patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or oral corticosteroid-dependent asthma. Our presenter will highlight key roles for Type 2 Inflammation in the pathobiology of asthma and the efficacy and safety data across three clinical trials in nearly 3,000 patients with asthma. Additionally, our presenter will lead an interactive discussion of different patient types who might be eligible for treatment.
